Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Emerging ADC Target Antigens in Solid Tumors

Antibody-drug conjugates (ADCs) combine the specificity of antibodies targeting tumor-associated antigens (TAAs) with the cytotoxicity of small molecule drugs, making ADCs a rapidly growing drug therapy for solid tumors. Sino Biological provides high-quality products for ADC target antigens to support the field of ADC therapy.

Featured Recombinant Proteins and Corresponding Antibodies

Sino Biological provides high-quality ADC target proteins, including established target antigens such as EGFR, FGFR, c-MET, and HER2, as well as emerging target antigens such as EpCAM, TROP-2, CD70, CD25, CD166, CEACAM5, GPNMB, Mesothelin, and more. These recombinant proteins have been validated for activity, and are trusted by users as indicated by citations in top-tier journals. The antibodies for these target antigens are also available with a variety of applications, such as ELISA, IHC-P, FCM, IP, and WB. 

Click for more ADC target proteins and corresponding antibodies.

More about ADC Targets:

CEACAMs: Promising ADC Targets

HER3: A Rising Star in Cancer Immunotherapy

[Application Note] Antibody-drug Conjugates: Smart Chemotherapeutics

Sino Biological Europe GmbH
Düsseldorfer Str. 40
65760 Eschborn
VAT nummer: DE323950120


Sino Biological Europe GmbH

Sänd till en kollega